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Background: To assess time-course changes in best-corrected visual acuity (BCVA) up to 
5 years after vitrectomy to treat idiopathic full-thickness macular holes (MHs) and identify the 
relationship of the changes to postoperative complications.
Methods: Twenty-three consecutive patients with an idiopathic MH underwent vitrectomy 
without adjuvant treatment. BCVA and complications were assessed postoperatively.
Results: Twenty-two of 23 (95.7%) MHs closed after the first surgery, with a final anatomic 
success rate of 100%. The time course of the BCVA was analyzed in 20 cases in which data 
were obtained for over 5 years. The BCVA improved by 0.43 logarithm of the minimum angle 
of resolution (logMAR) unit 6 months postoperatively (P , 0.001) and continuously improved 
by 0.05, 0.06, and 0.07 logMAR units between 6 months and 1 year, 1 year and 3 years (by 0.11 
logMAR unit between 6 months and 3 years; P = 0.049), and 3 years and 5 years (P = 0.018) 
postoperatively, respectively. Macular complications developed in seven (35%) of the 20 cases; 
the mean BCVA at 5 years in these cases was significantly (P , 0.001) worse than in cases 
without complications.
Conclusion: The BCVA might improve gradually for 5 years after vitrectomy to treat 
MHs. However, the macular complications that can develop postoperatively could limit that 
possibility.
Keywords: macula hole, time course, vitrectomy, retina, visual acuity, complication
Introduction
Kelly and Wendel,1 who first reported the effectiveness of vitrectomy for treating 
idiopathic macular holes (MHs), showed that best-corrected visual acuity (BCVA) 
might improve with anatomic closure of the MHs. Several methods, including 
removal of the internal limiting membrane (ILM) and use of adjuvants (transforming 
growth factor-beta 2 [TGF-β
2
] or autologous serum), were developed to improve the 
closure rate.2–7
Although the effectiveness of vitrectomy for treating MHs has been reported 
frequently, the follow-up periods were largely limited to 6 or 12 months, and most 
studies did not include a time-course analysis.
A few studies have reported follow-up periods exceeding 3 years after vitrectomy 
for idiopathic MHs. Leonard et al8 reported the  visual acuity (VA) time course up to 3 
years and continuous VA improvements after vitrectomy with TGF-β
2
 and without ILM 
removal for MHs; however, only 73% of the patients were followed for 3 years. Scott 
et al9 performed vitrectomy with TGF-β
2
 in 91% of the cases without ILM removal 
and reported the final VA after more than 5 years and the best VA. Haritoglou et al10 
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reported results after more than 3 years following vitrectomy 
with ILM peeling. Neither of these latter two studies included 
a time-course analysis.
Regarding complications, Leonard et al8 reported that 
one MH reopened after cataract surgery and no retinal 
detachments developed. Scott et al9 found that choroidal 
 neovascularization associated with age-related macular 
degeneration and retinal detachment resulted in decreased VA. 
Haritoglou et al10 reported that no MHs opened again after 
the initial closure and there was no cellular proliferation in 
the macular area.
The current study assessed the time-course changes in 
BCVA and postoperative complications during follow-up for 
5 years in patients with a MH after vitrectomy.
Methods
Patients
Twenty-three consecutive patients who presented to the Osaka 
University Hospital with full-thickness stage 2–4 idiopathic 
MH were enrolled in this uncontrolled interventional case 
study. The surgeries were performed from February 1998 
to April 1999.
Patients were excluded if symptoms persisted for longer 
than 1 year, if they had undergone a previous posterior 
surgery, or had glaucoma, retinal vein occlusion, high myopia 
exceeding −6.0 diopters, or systemic diseases that precluded 
maintaining a facedown position.
Preoperative data included patient age, sex, affected 
eye, spherical equivalent refraction, preoperative symptom 
duration, MH diameter in disc diameters (DD), MH stage 
(range, 2–4), lens status (phakia, pseudophakia, aphakia), 
and BCVA (Table 1). MH stage was based on Gass’s 
classification11 and confirmed by biomicroscopy and/or 
optical coherence tomography (OCT). MH diameter was 
calculated by averaging the vertical and horizontal lengths 
of MHs compared to the disc. BCVA was measured using 
the Landolt C VA chart. Manual refraction was performed 
when acuity was measured in this trial.
Surgical techniques
A standard three-port pars plana vitrectomy was performed 
by four surgeons. A posterior vitreous detachment (PVD) was 
created with active aspiration in cases without complete PVD. 
Intentional ILM peeling was not performed. If the vitreous 
cortex around the MHs was observed, it was gently removed 
using a diamond-dusted membrane scraper (DDMS) 
(Synergetic, St Charles, MO).12,13 The surface of the retina 
just around the MHs was gently scratched with DDMS, and 
the vitreous cortex attached to the edge of MHs was removed. 
Epiretinal membranes (ERMs) were removed if there were 
apparent ERMs. Combined phacoemulsification and intraocular 
lens implantation were performed after the patients received an 
explanation that progression of nuclear sclerosis after vitrectomy 
is not preventable in patients exceeding 50 years.14,15
Adjuvants or intravitreal injections of triamcinolone 
were not administered during any procedures. After 
fluid–air exchange, the air was exchanged for 12%–16% 
perfluoropropane. Patients remained facedown from 
immediately postoperatively for about 2 weeks. All patients 
provided written informed consent before any procedures 
were performed.
Main outcomes
Postoperative data recorded included BCVA, macular status 
(open/closed), and postoperative complications. BCVA data at 
6 months and 1, 3, and 5 years postoperatively were analyzed 
in this study. BCVA measured at 6 months ± 1 month, 
1 year ± 2 months, 3 years ± 2 months, and 5 years ± 2 months 
postoperatively was collected. A fundus examination 
and/or OCT was performed to detect macular changes and 
other complications postoperatively. Any intraoperative 
complications that developed were recorded.
To remove the influence of cataract surgery on the 
improvement of visual acuity, the relationship between 
cataract surgery and visual acuity was also analyzed.
Statistical analysis was performed using statistical analysis 
software (SigmaStat version 2.0; IBM, Armonk, NY). The 
data are expressed as the mean ± standard deviation. BCVA 
levels were converted to the logarithm of the minimum 
angle of resolution (logMAR) equivalents and analyzed. 
Mean BCVAs at each time point were compared using the 
Table 1 Preoperative characteristics (n = 23)
Age, years (range) 63.6 ± 5.8 (52–72)
Men (%) 14 (60.9)
right eye (%) 9 (39.1)
Preoperative 3.1 ± 2.3 (1–9) 
symptom duration (months)
refraction (D) −0.44 ± 2.23 (−5.25 to 3.5)
Phakic eyes (%) 23 (100.0)
MH diameter (DD) 0.21 ± 0.11 (0.05–0.46)  
(data missing from 
four eyes)
No stage 2/3/4 MHs (%) 13 (56.5%)/7  
(30.5%)/3 (13.0%)
BCVA (mean) 0.20 (0.04–0.8)
Note: refraction = spherical equivalent refraction.
Abbreviations: D, diopters; DD, disc diameter; MH, macular hole; BCVA, best-
corrected visual acuity.
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BCVA improved by 0.43 logMAR unit 6 months 
postoperatively compared with preoperatively (P , 0.001). 
BCVA improved by 0.05, 0.06, and 0.07 logMAR units 
between 6 months and 1 year, 1 year and 3 years (by 0.11 
logMAR unit between 6 months and 3 years; P = 0.049), and 
3 years and 5 years (P = 0.018) postoperatively, respectively. 
Therefore, BCVA improved more than 0.05 logMAR unit 
between time points even after 6 months postoperatively. 
The largest proportion of the improvement occurred 
within the initial 6 months after the surgeries. There were 
also significant differences between BCVAs at 6 months 
and 5 years (P = 0.001) and between 1 year and 5 years 
(P = 0.002) (Figure 1).
Figure 2 shows the distribution of BCVA at each 
time point. The percentage of cases in which BCVA was 
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Figure 1 Time-course changes in mean BCVA (logMAr units). 
Notes: The BCVA levels in Landolt C chart were converted to the logarithm of 
the minimum angle of resolution (logMAr) equivalents and analyzed. Mean BCVA 
improved continuously up to 5 years, even after 6 months. Asterisks indicate a 
significant difference. 
Abbreviations: BCVA, best-corrected visual acuity; Preop, preoperative; 
logMAr, logarithm of the minimum angle of resolution.
paired t-test, and t-tests were performed between the groups. 
Fisher’s exact test was performed to analyze the proportions 
between each group. P , 0.05 was considered significant.
Results
Follow-up
Data were obtained for more than 5 years (range, 
61–100 months; mean, 83.4 ± 10.5 months) in 20 of 23 cases. 
Preoperative BCVA levels in these cases ranged from 0.04 to 
0.8 (mean, 0.19) in Landolt C VA. The mean patient age was 
62.5 ± 5.3 years, and the refractive error was −0.44 ± 2.23 
diopters. The mean MH diameter was 0.21 ± 0.11 DD (range, 
0.05–0.46). Ten, seven, and three eyes had stage 2, 3, and 
4 MHs, respectively. All cases were phakic.
Three patients who had a stage 2 MH preoperatively 
could not keep their follow-up appointments because of 
new systemic diseases or relocation to a distant town. Those 
MHs closed after the first vitrectomy. Preoperative BCVA 
was 0.3 in all eyes, and BCVA improved to 0.5 at 1 year 
in one case, to 0.7 at 1 year in another case, and to 0.8 at 
1 year and 1.0 at 3 years in the third case. No postoperative 
complications developed during the follow-up periods (1, 1, 
and 3 years, respectively).
Surgery
Combined cataract surgery was performed in 18 (78.3%) cases. 
A PVD was created with active aspiration in 20 of 23 cases. 
Two cases underwent ERM removal, and the vitreous cortex 
around the MHs was removed using a DDMS in twelve of 
23 cases. ILM peeling was not performed, although the DDMS 
might have scratched the ILM surface just around the MHs. 
Mean surgical time was 61.6 ± 13.4 minutes.
MHs closed in 22 (95.7%) of the 23 eyes postoperatively. 
Another vitrectomy was performed 2 months after the first 
surgery in one patient (age, 55 years) in whom the MH 
did not close after the first surgery; successful closure was 
achieved after the second surgery. Preoperative BCVA 
was 0.1, refractive error was −0.25 diopter, preoperative 
duration of symptoms was 9 months, and MH diameter 
was 0.46 DD.
Postoperative BCVA time course
The time course of the BCVA was analyzed in the 20 cases up 
to 5 years (Figure 1). Mean BCVA improved continuously up 
to 5 years, even after 6 months. BCVAs at 6 months and 1, 3, 
and 5 years postoperatively ranged from 0.1 to 1.0 (mean, 
0.50), 0.1 to 1.2 (mean, 0.56), 0.2 to 1.2 (mean, 0.64), and 
0.2 to 1.2 (mean, 0.75) in Landolt C VA, respectively.
Preop
6 months
1 year
3 years
5 years
0% 20% 40% 60% 80% 100%
<0.1
0.1
0.2
0.5 <1.0
<0.5
<0.2≤
≤
≤
≥1.0
Figure 2 Distribution of BCVA values at each time point. 
Notes: The percentage of cases with BCVA of 1.0 or better gradually increased and 
reached 45%. No case had BCVA worse than 0.1 5 years postoperatively. 
Abbreviations: BCVA, best-corrected visual acuity; Preop, preoperative.
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1.0 or better in Landolt C VA increased during follow-up 
and reached 45% (nine cases) at 5 years postoperatively. 
The percentage of cases in which BCVA was 0.5 or higher 
reached 90% (18 cases). No case had BCVA below 0.1 at 
5 years. BCVA improved three or more lines in 75% (15/20) 
of cases 5 years postoperatively.
BCVA values in the case in which the MH closed after 
the second surgery were 0.1, 0.4, 0.4, 0.7, and 0.6 in Landolt 
CVA preoperatively, at 6 months, and 1, 3, and 5 years 
postoperatively, respectively.
Postoperative complications and BCVA
No holes recurred in any eyes during the follow-up period. 
No retinal detachments or tears developed intraoperatively 
or postoperatively.
Five of the 20 cases that did not undergo simultaneous 
cataract surgery combined with vitrectomy developed 
cataracts postoperatively. Macular complications developed 
postoperatively: cystoid macular edema (CME) (n = 1), 
chorioretinal degeneration (n = 1), and epiretinal proliferation 
(n = 5) in seven of the 20 cases during follow-up to 5 years 
(Table 2). No other complications developed intraoperatively 
or postoperatively.
CME was observed 6 months after vitrectomy in one 
eye and required another vitrectomy with ILM  peeling 
without adjuvants. The BCVA in this case changed 
from 0.3 preoperatively to 0.5 in Landolt C VA at 5 years 
postoperatively.
Chorioretinal degeneration with depigmentation 
of the retinal pigment epithelium developed 2 months 
postoperatively in the foveal area of one eye. BCVA was 0.05 
preoperatively, improved to 0.1 6 months postoperatively, 
and then varied between 0.1 and 0.2. BCVA at 5 years was 
0.2 in Landolt C VA. This case had a stage 4 MH and closed 
successfully.
BCVAs in five cases in which epiretinal proliferation 
developed within the 5 years of follow-up changed from 0.04, 
0.3, 0.3, 0.4, and 0.5 preoperatively to 0.6, 0.5, 0.7, 0.4, and 
1.0 5 years postoperatively in Landolt C VA, respectively. 
The first apparent epiretinal proliferation was found in 
one case 1.5 years postoperatively. Two of the five cases 
with postoperative epiretinal proliferation were those that 
underwent ERM removal during vitrectomy for a MH.
Mean BCVA was 0.93 in Landolt C VA in cases without 
complications 5 years postoperatively. Mean BCVA was 
0.51 in cases with complications 5 years postoperatively. 
The difference between these two groups was significant 
(P = 0.0009), although there was no difference between the 
two groups preoperatively (P . 0.05). In cases without com-
plications, 84.6% had a BCVA improvement of 0.3 logMAR 
unit or more 5 years postoperatively, compared with 57.1% 
cases with complications. The percentage of cases without 
complications with BCVA of 1.0 or higher increased gradu-
ally and reached 61.5% 5 years postoperatively. However, the 
percentage of cases with complications was 14.3%.
Cataract surgery and BCVA
Combined cataract surgery was performed in 18 (78.3%) of 
23 cases. Data were obtained for more than 5 years in 15 of 
the 18 cases. Mean BCVAs in these cases were 0.15 (range, 
0.04–0.5), 0.45 (range, 0.1–1.0), 0.54 (range, 0.1–1.2), 0.56 
(range, 0.2–1.2), and 0.67 (range, 0.2–1.2) in Landolt C VA, 
preoperatively, at 6 months, 1, 3, and 5 years postoperatively, 
respectively. There were significant differences between 
BCVAs at 6 months and 5 years (P = 0.011), between 1 year 
and 5 years (P = 0.047), and between 3 years and 5 years 
(P = 0.047).
Phacoemulsification and intraocular lens implantation 
were performed in two eyes within 1 year after vitrectomy, 
in two eyes between 1 and 2 years, and in one eye between 2 
and 3 years among the cases in which simultaneous cataract 
surgery combined with vitrectomy was not performed. Mean 
BCVAs in these cases were 0.8 (range, 0.6–1.0), 0.82 (range, 
0.6–1.0), 0.86 (range, 0.5–1.0), and 1.08 (range, 1.0–1.2) in 
Landolt C VA at 6 months and 1, 2, and 3 years after cataract 
surgery, respectively. There was a significant difference 
between BCVAs at 6 months and at 3 years (P = 0.012) 
and between 1 year and 3 years (P = 0.015) after cataract 
surgery.
No postoperative macular complications developed in 
the cases that did not undergo simultaneous cataract surgery. 
All five cases (100%) treated with vitrectomy followed by 
cataract surgery achieved BCVA of 1.0 or better, while four 
Table 2 Postoperative complications
Complication  
(number of cases)  
Onset after surgery Treatment
Cataract (n = 5)  0.5–2.5  
(mean 1.4 ± 0.74) years
Cataract surgery
Cystoid macular  
edema (n = 1)
6 months PPV with ILM  
removal
Chorioretinal 
degeneration (n = 1) 
2 months None
Epiretinal  
proliferation (n = 1)
1.5–5  
(mean 2.7 ± 1.4) years 
None
Note: Cataract surgery refers to phacoemulsification and intraocular lens implantation.
Abbreviations: PPV, pars plana vitrectomy; ILM, internal limiting membrane.
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of 15 cases (26.7%) treated with vitrectomy combined with 
simultaneous cataract surgery achieved that level of BCVA 
(P = 0.008, Fisher’s exact test), although the preoperative VA 
in these two groups did not differ significantly (P . 0.05).
Discussion
We investigated if BCVA continues to improve to a minimum 
of 5 years after vitrectomy for MHs. In a 2-year time-course 
study, Ezra and Gregor16 reported that final BCVA was better 
than at 1 year. They theorized that this improvement resulted 
from cataract surgery having been performed, in 72.2% of the 
cases, between 1 and 2 years after vitrectomy. In the current 
study, cataract surgery was performed after vitrectomy 
in 25% of our cases, and the surgery was performed 
simultaneously with vitrectomy in 75%. The percentage of 
our cases that underwent cataract surgery after vitrectomy 
was lower than that reported by Ezra and Gregor.16 In the 
current study, cataract surgery was performed in five eyes 
with time periods within 1 year, between 1 and 2 years, and 
between 2 and 3 years after vitrectomy. Thus, all cataract 
surgeries were performed before 3 years after vitrectomy. 
Mean BCVA in all of the current cases significantly increased, 
even after 3 years postoperatively. This result suggested that 
reasons other than cataract surgery were responsible for the 
BCVA improvement. Mean BCVA for the 15 cases in which 
combined cataract surgery with vitrectomy was performed 
increased significantly postoperatively. Moreover, mean 
BCVA for the five cases in which cataract surgery was 
performed after vitrectomy also significantly improved in the 
time course immediately after cataract surgery. These results 
also suggested that reasons other than cataract surgery were 
responsible for the BCVA improvement. Foveal function 
with reconstruction of the foveal microstructure might have 
been a factor. We reported previously that reconstruction of 
the foveal microstructure might improve visual function17 
during a 1-year follow-up period. The foveal microstructure 
might gradually improve even after 1 year postoperatively, 
with resultant improvement of visual function. In this study, 
the foveal microstructure was not examined because time-
domain OCT,which was used in this study, could not show 
the details of foveal microstructure, such as inner segment/
outer segment junction. That was one of the limitations in 
this study.
BCVA improved by 0.43 logMAR unit 6 months 
postoperatively compared with preoperatively. BCVA 
improved by 0.05, 0.06, and 0.07 logMAR units between 
6 months and 1 year, 1 year and 3 years, and 3 years 
and 5 years postoperatively, respectively. Thus, BCVA 
improved more than 0.05 logMAR unit between time 
points even after 6 months postoperatively up to 5 years 
postoperatively. Meanwhile, the largest proportion of the 
improvement occurred within the initial 6 months after the 
surgeries. Wittich et al18 examined acuity recovery rate after 
MH surgery, and using hierarchical linear modeling with 
linear and curvilinear regression analysis showed that most 
recuperation occurred during the initial 6 months after MH 
surgery (follow-up, 6–23 months). The data corresponded 
to our result.
BCVAs of 0.5 or better and 1.0 or better in Landolt C VA 
increased gradually during follow-up and reached 90% and 
45% at 5 years postoperatively, respectively, in the current 
study. Scott et al9 reported a final VA of 20/40 or higher in 
58% of cases, which was lower than in the current study. 
One reason for the difference was the preoperative status of 
the study cases; the duration between the onset of subjective 
symptoms and surgery in their study ranged from 1.1 to 
93.8 months, compared with 1–9 months in the current 
study. Another possibility is the surgical method; most of 
the cases of Scott et al9 included a TGF-β protocol, which 
might have affected the long-term results. We did not use 
adjuvants in our cases.
In the current study, the rate of MH closure exceeded 
95% after the first surgery, and we achieved a 100% final 
closure rate. The MH closure rates after vitrectomy without 
ILM peeling have ranged from 57.7% to 89%.1,2,5,9,19 The 
rate in the current study was relatively higher than in 
those reports and the same in cases with ILM peeling or 
adjuvants, which also might have resulted from differences 
in preoperative status. Another possibility is that we used 
a DDMS intraoperatively.12,13 With the DDMS, the surface 
of the ILM can be scratched, and a focal area of ILM might 
be peeled.
Several complications developed after vitrectomy for 
idiopathic MHs in the current study during a long follow-up 
period that limited the improvement in visual function 
after MH closure. CME and chorioretinal degeneration 
developed within 1 year postoperatively, and BCVA did not 
reach 1.0 at 5 years postoperatively. Epiretinal proliferation 
might have resulted from the long-term response caused 
by injury to a portion of the Müller cells or inflammation 
intraoperatively and postoperatively and developed gradually 
in 25% of our cases. BCVA reached 1.0 in only one case with 
epiretinal proliferation. ERMs could have prevented BCVA 
improvement after MH closure. Most surgeons now remove 
the ILM during MH surgery. This procedure might minimize 
the recurrence of idiopathic ERMs.20 Thus this procedure 
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may prevent epiretinal formation in the long term after 
vitrectomy to treat MH. In fact, Haritoglou et al10 reported 
no ERM formation during a follow-up period that exceeded 
36 months after vitrectomy with ILM removal for MHs. ILM 
removal might improve the rate of MH closure and prevent 
ERM formation after vitrectomy for MHs.
Analysis of the time-course changes in BCVA and 
postoperative complications up to 5 years after vitrectomy 
for consecutive MH cases suggested the possibility of gradual 
improvement in visual function and the limitations of the 
improvement if macular complications occur. A randomized 
control study should evaluate the effectiveness of ILM 
removal during vitrectomy for MHs to prevent ERM 
formation as a macular complication.
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